健康元：LZM012项目银屑病适应症预计本年内申报上市

Core Viewpoint - The company Health元 is preparing to submit a listing application for the LZM012 project for psoriasis indication within this year, having received consent for a priority review application from the CDE [2]. Group 1: Project Development - The LZM012 project is expected to have its listing application submitted by the end of this year [2]. - The company has communicated with the drug review center (CDE) regarding the priority review application and has received approval [2]. - The application for priority review will be submitted simultaneously with the drug listing application [2]. Group 2: Future Plans - The company is currently in discussions with relevant parties regarding the details of external authorization cooperation and is conducting due diligence [2]. - Any progress in these discussions will be announced in a timely manner [2].